Executive Summary / Key Takeaways

• Healthy Extracts Inc. is undergoing a significant transformation, pivoting from historical losses to a growth-focused nutraceutical innovator, driven by proprietary plant-based technologies and strategic acquisitions.
• The company's recent acquisition of Gummy USA LLC and exclusive rights to a revolutionary oral delivery technology are set to accelerate revenue, with 2025 net revenue guidance increasing to over $6.3 million, representing over 102% growth.
• Financial performance shows a positive shift, with record 2024 net revenue and the first-ever positive Adjusted EBITDA, alongside strong Q2 2025 revenue growth and net income, indicating improving operational efficiency.
• Despite these growth catalysts, Healthy Extracts faces substantial liquidity challenges and a "going concern" qualification, necessitating further capital raises that will likely be dilutive to existing shareholders.
• The investment thesis hinges on the company's ability to successfully integrate its new acquisitions, leverage its technological differentiators to capture market share in high-growth health segments, and achieve sustained profitability to address its capital structure.

The Genesis of a Nutraceutical Innovator

Healthy Extracts Inc. (HYEX) has evolved from its origins as Grey Cloak Tech Inc., incorporated in 2014, into a dedicated platform for acquiring, developing, patenting, marketing, and distributing plant-based nutraceuticals. This strategic pivot, marked by a name change in 2020, positioned the company to target high-growth categories within the multibillion-dollar nutraceuticals market, including heart, brain, immune, and increasingly, gut health. The company's mission is clear: to acquire or create products with health and performance benefits that resonate with a mass consumer appeal.

The foundational pillars of this strategy were laid through key acquisitions. In fiscal 2019, Healthy Extracts acquired BergaMet NA, LLC, bringing heart and immune health products into its portfolio. This was followed by the acquisition of Ultimate Brain Nutrients, LLC (UBN) in April 2020, expanding its reach into brain health. These early moves established the company's core business model, focusing on proprietary and patented formulations.

Technological Edge: Innovation in Delivery and Formulation

Healthy Extracts differentiates itself through its commitment to innovative, plant-based nutraceuticals and advanced delivery systems. Its BergaMet NA, LLC products, for instance, are backed by published third-party research suggesting their ability to support heart health, immune response, and address metabolic syndrome. Similarly, its Ultimate Brain Nutrients offerings target cognitive wellness.

A significant technological leap occurred in 2025 with the company securing exclusive rights to a revolutionary oral delivery technology for nutritional supplements through a joint product development agreement with Lelantos Fibre. This collaboration introduces a unique fiber straw system designed to deliver healthy nutrients as consumers sip. The tangible benefit of this technology is its ability to deliciously and conveniently integrate supplements into daily routines, expanding the company's portfolio of unique nutritional supplement delivery systems. This innovation directly taps into the burgeoning $51 billion gut health market, exemplified by the launch of the "WHITNEY JOHNS™ Gut Health Straw™," the world's first prebiotic fiber and probiotic supplement delivered via this drinking straw technology. This technological differentiation enhances Healthy Extracts' competitive moat by offering novel, user-friendly product formats that can command premium pricing and foster customer loyalty, thereby contributing to higher average selling prices and improved margins.

Strategic Expansion and Accelerated Outlook

The company's strategic trajectory gained significant momentum with the transformative acquisition of Gummy USA LLC (GUSA) on July 19, 2025. This acquisition, which made GUSA a wholly-owned subsidiary, involved the issuance of 13.08 million shares of common stock, representing 77.50% of Healthy Extracts' issued and outstanding common stock after the transaction. The sole member of GUSA was also granted anti-dilution rights, underscoring the strategic importance of this merger.

This acquisition has dramatically reshaped Healthy Extracts' near-term financial outlook. The company increased its 2025 net revenue guidance from an initial $4.2 million+ to an impressive $6.3 million+, projecting over 102% growth. This revised guidance, up from a previous expectation of 34%+ growth, highlights the immediate and substantial impact of integrating Gummy USA into the Healthy Extracts ecosystem. The strategic intent behind this expansion is to leverage GUSA's capabilities to accelerate revenue growth and further diversify the product portfolio within the broader nutraceutical market.

Financial Performance: A Turn Towards Profitability

Healthy Extracts' recent financial performance reflects a company in transition, showing clear signs of operational improvement and a shift towards profitability. For the six months ended June 30, 2025, the company reported net revenue of $1.90 million, a 19% increase from $1.60 million in the same period of 2024. Quarterly revenue for Q2 2025 also saw a healthy 7% increase to $968,656, compared to $908,389 in Q2 2024.

Gross profit for the six months ended June 30, 2025, reached $1.02 million, up 14% from $894,446 in the prior year. Notably, the cost of revenue as a percentage of revenues decreased to 39% in Q2 2025 from 46% in Q2 2024, indicating improved efficiencies driven by increased revenue. While general and administrative expenses rose by 27% to $1.23 million for the six months ended June 30, 2025, management attributes this increase primarily to higher advertising and consulting fees directly aimed at driving revenue growth. This strategy appears to be yielding results, as the company reported a net income of $331,739 for the six months ended June 30, 2025, a significant improvement from a net loss of $747,758 in the prior year period.

For the full year 2024, Healthy Extracts achieved record financial results, including its first-ever positive Adjusted EBITDA of $0.02 per share, driven by strong subscription-based recurring revenue growth. This marks a critical milestone, demonstrating the company's ability to generate operating profits. However, despite these positive trends, the company reported net cash used in operating activities of $77,237 for the six months ended June 30, 2025, a reversal from the $187,809 provided by operating activities in the prior year. This shift was influenced by various factors, including changes in inventory and lease liabilities. Cash on hand as of June 30, 2025, stood at $200,495.

Competitive Landscape: Niche Innovation vs. Scale

Healthy Extracts operates in a competitive nutraceutical market, positioning itself as a specialized innovator against larger, more diversified players. Key publicly traded competitors include Herbalife Nutrition Ltd. (HLF), Nu Skin Enterprises, Inc. (NUS), LifeVantage Corporation (LFVN), and Mannatech, Incorporated (MTEX).

Healthy Extracts' gross profit margin of 59.56% (TTM) indicates a solid foundation, though it trails the higher margins seen in some larger competitors like Herbalife (78%), LifeVantage (79%), and Mannatech (78%), and is slightly below Nu Skin (68%). This suggests that while Healthy Extracts' proprietary formulations offer value, there may be opportunities for further cost optimization or enhanced pricing power. The company's operating profit margin (-9.46% TTM) and net profit margin (-12.42% TTM) are currently negative, contrasting with the positive margins of Herbalife (8% operating, 5% net), LifeVantage (2% operating, 1% net), and Mannatech (1% operating, 2% net). Nu Skin also reported negative operating and net margins (-9% and -8% respectively), but less severely than Healthy Extracts. This disparity highlights Healthy Extracts' challenge in scaling its operations and managing general and administrative expenses efficiently to achieve consistent bottom-line profitability, despite its revenue growth.

Healthy Extracts' strength lies in its focused approach on specific health categories like heart, brain, and gut health, bolstered by its proprietary plant-based formulations and innovative delivery systems. The new oral delivery technology, for instance, provides a unique product differentiation that larger, more generalized competitors may not offer. However, its smaller scale and comparatively lower brand recognition present vulnerabilities against the extensive distribution networks and established customer bases of companies like Herbalife and Nu Skin. The company's debt-to-equity ratio of 2.00 (TTM) is higher than most peers (LifeVantage 0.52, Nu Skin 0.73, Mannatech 0.78), indicating a more leveraged capital structure, though Herbalife has negative equity. This higher leverage could impact financial flexibility and the cost of future capital. While direct quantitative comparisons of market share are challenging to ascertain for all niche competitors, Healthy Extracts' strategic acquisitions and technological advancements are critical to carving out and expanding its presence in a fragmented market.

Liquidity and Capital Strategy

Despite recent positive financial momentum, Healthy Extracts acknowledges substantial doubt about its ability to continue as a going concern within one year from the financial statement issuance date. This is primarily due to accumulated net losses totaling $19.57 million since its inception through June 30, 2025. The company's slightly negative operating cash flow in the first half of 2025 further underscores this challenge.

Management's strategy to mitigate this risk involves actively seeking additional funding through debt and equity financing. While this approach is necessary to support growth and meet short- to medium-term cash needs, it also carries the inherent risk of dilution for existing stockholders. The recent Gummy USA acquisition, which involved issuing a significant number of shares, exemplifies this strategy. The company's ability to transition to consistently positive cash flows from operations will be paramount to its long-term financial stability and reducing reliance on external capital. Cash on hand as of June 30, 2025, stood at $200,495.

Risks and Challenges

Investing in Healthy Extracts carries several key risks. The most prominent is the "going concern" qualification, which highlights the company's historical accumulated losses and the ongoing need for external financing. There is no guarantee that such financing will be available on favorable terms, or at all, and any equity financing will likely result in further dilution for shareholders.

Operational risks include the successful integration of new acquisitions like Gummy USA and the effective commercialization of new technologies such as the oral delivery system. While these initiatives offer significant growth potential, execution challenges could impact financial performance. Furthermore, the company's disclosure controls and procedures were deemed "not effective at the reasonable assurance level" as of June 30, 2025, due to identified material weaknesses, which could pose risks to financial reporting integrity and investor confidence.

Conclusion

Healthy Extracts Inc. is at a pivotal juncture, demonstrating a clear strategic vision to transform into a leading innovator in the plant-based nutraceutical market. The company's commitment to proprietary technology, exemplified by its BergaMet and KETONOMICS lines, and its aggressive pursuit of novel delivery systems like the fiber straw technology, positions it well within high-growth health segments. The recent acquisition of Gummy USA and the subsequent upward revision of 2025 net revenue guidance to over $6.3 million underscore a compelling growth narrative, suggesting that strategic M&A and technological differentiation are beginning to yield tangible results.

While the company has made commendable strides towards operational efficiency and achieved its first-ever positive Adjusted EBITDA in 2024, the "going concern" qualification and the need for further capital remain critical considerations for investors. The investment thesis for Healthy Extracts hinges on its ability to sustain its impressive revenue growth, effectively integrate new assets, and translate its technological leadership into consistent, scalable profitability. Success in these areas would not only solidify its competitive standing against larger rivals but also address its liquidity challenges, paving the way for long-term value creation in the dynamic nutraceutical industry.